Showing results by publisher "Tantor Media" in Biotechnology

In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading. Coming at a time of economic recession and declining technological competitiveness in the United States, the event ignited a period of speculative frenzy over biotechnology.

In Regenesis, George Church and science writer Ed Regis explore the possibilities of the emerging field of synthetic biology. Synthetic biology, in which living organisms are selectively altered by modifying substantial portions of their genomes, allows for the creation of entirely new species of organisms. These technologies - far from the out-of-control nightmare depicted in science fiction - have the power to improve human and animal health, increase our intelligence, enhance our memory, and even extend our life span. 

Shortly after the emergence of genetic engineering in the 1970s, academic biologists were courted by venture capitalists and multinational companies. Researchers who understood the new biology of the time went from being merely curious about how the natural world functioned to realizing that they could profit from their newfound recognition. As they were inventing all sorts of newfangled organisms, biologists became acquainted with intellectual property.